LC-MS Sensitivity Optimization Using DoE

When Your Instrument Can’t Meet Detection Limits

You’ve developed a method. Run your samples. But the detection limits fall short of regulatory requirements. Your sponsor needs 26.7 ng/g, but you’re only achieving 400 ng.

The conventional response? Recommend purchasing more sensitive instrumentation—a costly solution that may take months to procure and validate.

But what if your current equipment is more capable than you realize?

Watch: How DoE Unlocked 438% Sensitivity Improvement

In this video, Resolian analytical scientist Adam shares a method development breakthrough that challenges the “buy new equipment” default response. Faced with poor analyte response for 1,4-Dinitrosopiperazine (DNPZ) detection, Adam used Design of Experiments (DoE) to unlock hidden sensitivity in existing LC-MS instrumentation.

What You’ll Learn in This Video:

  • The limitations of traditional one-factor-at-a-time optimization approaches
  • How DoE enables simultaneous optimization of multiple parameters in fewer runs
  • The specific source and StepWave parameters that impact sensitivity
  • Real comparative data: signal-to-noise of 16 vs. 86 on the same compound
  • Cost and sustainability implications of maximizing existing equipment
  • How this methodology applies to future challenging nitrosamine analyses

Adam’s approach using Modde software optimized both source and StepWave parameters on a Xevo TQ-S simultaneously – achieving the sponsor’s required detection limits without any new capital investment.

Why This Matters Beyond One Method

The pharmaceutical industry faces increasing pressure to detect nitrosamines and other genotoxic impurities at ever-lower concentrations. Simultaneously, there’s growing emphasis on sustainable, cost-effective laboratory practices.

DoE methodology addresses both priorities by:

  • Maximizing current instrumentation capabilities before considering purchases
  • Reducing method development time through systematic, efficient optimization
  • Supporting green analytical chemistry by avoiding unnecessary equipment manufacturing and disposal
  • Providing reproducible, statistically sound optimization compared to trial-and-error approaches
  • Creating transferable knowledge applicable to future challenging compounds

Expert Method Development Support

Not every analytical challenge requires a capital equipment solution. Sometimes it requires a different approach – and a partner who knows how to extract maximum performance from your existing capabilities.

Resolian’s analytical sciences department specializes in complex method development for pharmaceutical impurity testing, including challenging nitrosamine analyses. Our team combines advanced statistical tools like DoE with deep LC-MS expertise to develop robust, fit-for-purpose methods that meet your most stringent requirements.

Whether you’re facing detection limit challenges, dealing with difficult analytes, or looking to optimize existing methods, we bring the systematic problem-solving approach that turns analytical obstacles into solutions.

Download Poster

Download a copy of the poster discussed here.

Ready to unlock your instrument’s full potential?

Contact our analytical sciences team to discuss how DoE and expert method development can address your specific challenges.

Scroll to Top

Zhiyang Zhao, Ph.D.

Chief Scientific Officer

Zhiyang Zhao, Ph.D., serves as Chief Scientific Officer (CSO) at Resolian. Dr. Zhao has over 30 years of pharmaceutical industry experience with special focus on drug metabolism and bioanalysis of small and large molecules in drug discovery and development. Dr. Zhao has previously held positions at Pfizer, GlaxoSmithKline, and Amgen. Before joining Resolian in 2015, Dr. Zhao served as Site Director of Preclinical Research at Amgen in Cambridge, Massachusetts, for over a decade. 

Currently, Dr. Zhao serves as an Adjunct Professor at the Eshelman School of Pharmacy of the University of North Carolina at Chapel Hill, North Carolina, and as Editor-in-Chief of Drug Metabolism & Bioanalysis Letters, a journal by Bentham Science, which publishes in all areas of drug metabolism and bioanalysis. Dr. Zhao received his Ph.D. degree in Medicinal Chemistry from Virginia Polytechnic and State University (popularly known as Virginia Tech) in Blacksburg, Virginia. 

 

Patrick Bennett

Chief Executive Officer

Patrick Bennett has over 35 years of experience in pharmaceutical analysis and laboratory management. Now Chief Business Officer at Resolian, Patrick’s experience includes the roles of Strategic Marketing Director for Pharma with Thermo Fisher Scientific, LabCorp, and Vice President of Strategy and Development with PPD. 

Patrick earned a B.S. degree in Toxicology and a M.S. degree in Pharmacology from the College of Pharmacy and Allied Health at St. John’s University and an M.B.A in International Marketing from the Martin J. Whitman School of Management at Syracuse University.